Outlook Therapeutics (OTLK) Other Accumulated Expenses (2018 - 2026)

Outlook Therapeutics (OTLK) has reported Other Accumulated Expenses for 9 consecutive years, with $191542.0 the latest figure, recorded in Q1 2026.

• In Q1 2026, Other Accumulated Expenses fell 78.63% year-over-year to $191542.0; the TTM figure through Mar 2026 stood at $191542.0 (down 78.63% YoY), while the FY2025 annual figure was $1.2 million, up 209.14% from the prior year.
• Other Accumulated Expenses slipped to $191542.0 in Q1 2026 per OTLK's latest filing, from $359055.0 in the prior quarter.
• Across five years, Other Accumulated Expenses topped out at $5.3 million in Q2 2023 and bottomed at $63220.0 in Q4 2024.
• Historically, Other Accumulated Expenses has averaged $897917.4 across 5 years, with a median of $426386.0 in 2023.
• Annual changes were most pronounced in 2022 — Other Accumulated Expenses jumped 744.62% — and 2024, when it tumbled 92.51%.
• Outlook Therapeutics' Other Accumulated Expenses stood at $1.2 million in 2022, then tumbled by 85.33% to $181072.0 in 2023, then plunged by 65.09% to $63220.0 in 2024, then jumped by 467.95% to $359055.0 in 2025, then slumped by 46.65% to $191542.0 in 2026.
• Business Quant data shows OTLK's Other Accumulated Expenses at $191542.0 in Q1 2026, $359055.0 in Q4 2025, and $1.2 million in Q3 2025.